Global

CN EN
  1. HOME
  2. ABOUT US
    About Laekna Core Management Team Board of Directors Milestones Scientific Advisory Board Core Investors Honors & Awards
  3. R&D
    R&D Therapeutic Areas Candidates Pipeline Clinical Trials
  4. PARTNERSHIPS
    Strategic Partners Business Development Holistic Approach BD Contact
  5. INVESTORS
    Corporate Governance Financial Results Announcements and Circulars IR Calendar Listing Documents
  6. NEWS
    Press Releases Media Coverage
  7. CAREERS
    Global Team Career Development Jobs My Laekna
  8. CONTACT US
    Contact Us Leave Message
  9. RSS Feeds
NEWS
PRESS CENTER

Scroll down to see more

Latest Articles
Media Coverage Press Releases
Search
  1. 2026-02-12
    Nature Communications, February Issue | Afuresertib Plus Fulvestrant Was Well Tolerated and Had Promising Anti-Tumor Activities Against Pretreated, Advanced HR-positive, Her2-negative Breast Cancer
    Nature Communications, February Issue | Afuresertib Plus Fulvestrant Was Well Tolerated and Had Promising Anti-Tumor Activities Against Pretreated, Advanced HR-positive, Her2-negative Breast Cancer
    More
    More
    More
  2. 2026-01-14
    A Novel PI3Kα Pan-Mutant Selective Inhibitor | Laekna Announced FDA Acceptance of Investigational New Drug Application for LAE118
    More
  3. 2025-12-31
    Laekna Announced First Subject Dosed in Phase I Single Ascending Dose Study of LAE103
    More
  4. 2025-12-22
    Laekna Announced First Subject Dosed in Phase I Multiple Dose Expansion Study of LAE102 for the Treatment of Obesity
    More
  5. 2025-12-15
    Laekna announced completion of patient enrollment in phase III clinical trial (AFFIRM-205) of LAE002 (AFURESERTIB) in breast cancer
    More
  6. 2025-11-12
    Laekna entered into an exclusive licensing agreement with Qilu Pharma for LAE002 (AFURESERTIB), an innovative drug candidate for the treatment of breast cancer in China
    More
  7. 2025-10-21
    Voluntary Announcement | Preliminary Results from The Phase I MAD Study LAE102 Demonstrated Encouraging Trend Towards Lean Body Mass Increase and Fat Mass Reduction
    More
123412
Media contact
communication@laekna.com
RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation

News

Positions

Follow us on Linkedin

  1. HOME
  2. ABOUT US
  3. R&D
  4. PARTNERSHIPS
  5. INVESTORS
  6. NEWS
  7. CAREERS
  8. CONTACT US

Copyright © Laekna Therapeutics, All Rights Reserved.  沪ICP备17047795号 Privacy Policy

Follow us on Linkedin

Follow us on Wechat